Location of Repository

Challenges in the harmonization of immune monitoring studies and trial design for cell-based therapies in the context of hematopoietic cell transplantation for pediatric cancer patients

By Stefan Nierkens, Arjan C. Lankester, R. Maarten Egeler, Peter Bader, Franco Locatelli, Michael A. Pulsipher, Catherine M. Bollard and Jaap Jan Boelens


Clinical trials aimed at improving results of hematopoietic cell transplantation (HCT) by adjuvant cell-based interventions in children have been limited by small numbers and pediatric-specific features. The need for a larger number of pediatric HCT centers to participate in trials has resulted in a demand for harmonization of disease-specific clinical trials and immune-monitoring. Thus far, most phase I/II trials select different end points evaluated at disparate time points, making inter-study comparisons difficult and, sometimes, impossible. In this review, we discuss the various aspects that are important to consider for harmonizing clinical trial design as well as the critical elements for standardized (immune)-monitoring protocols in cell-based intervention trials in the context of HCT. Comparison data from trials applying harmonized trial design will lead to optimized immunotherapeutic treatment protocols to maximize clinical efficacy while minimizing toxicity

Topics: Cell based therapy, Clinical trial design, Hematopoietic cell transplantation, immune monitoring, Pediatric cancer, Immunology, Immunology and Allergy, Oncology, Genetics(clinical), Transplantation, Cancer Research, Cell Biology
Year: 2015
OAI identifier: oai:dspace.library.uu.nl:1874/332480
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://dspace.library.uu.nl:80... (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.